Table 2.
Striatal L-DOPA, Dopamine, And Dopac Levels at two to Four Months After Gene Transfer as Measured by In Vivo Microdialysis
|
pg/ml catecholamine in dialysate |
|||
|---|---|---|---|
| Condition | L-DOPA | Dopamine | DOPAC |
| pTH-NFHth/ires/aadc | 1.6 ± 0.3 × 102 | 3.2 ± 0.2 × 102* | 1.3 ± 0.3 × 105* |
| pTH-NFHlac and 6-OHDA only | 1.0 ± 0.1 × 102 | 2.0 ± 0.4 × 102 | 3.1 ± 1.5 × 104 |
| Normal rats | 4.6 ± 0.3 × 102* | 5.8 ± 1.1 × 102* | 3.7 ± 0.3 × 105* |
The mean ± SEM of each catecholamine in each group are shown. For the pTH-NFHth/ires/aadc group (n = 5 rats), dialysate was collected from 4 rats at 3.5 months after gene transfer and from 1 rat at 4.0 months after gene transfer. For the pTH-NFH-lac and 6-OHDA lesioned only group (n = 4 rats), dialysate was collected from 2 rats that received pTH-NFHlac at 2.5 months after gene transfer, and dialysate was collected from 2 rats that received only 6-OHDA at 2.0 months after lesioning. The normal group (n = 5 rats) contained age-matched control rats that did not receive either 6-OHDA lesioning or gene transfer. The levels of L-DOPA, dopamine, and DOPAC Were determined in each dialysate sample. The asterisks indicate statistically significant differences compared to the pTH-NFHlac and lesioning only group (p < 0.05, ANOVA).
L-DOPA, levodopamine; DOPAC, ; 6-OHDA, 6-hydroxydopamine; SEM, standard error of the mean; ANOVA, analysis of variance.